default author photo

Carly Young

University of Cape Town (UCT) - South African Tuberculosis Vaccine Initiative

SCHOLARLY PAPERS

1

DOWNLOADS

116

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Safety, Reactogenicity, and Immunogenicity of Mtbvac in Infants: A Phase 2a Randomized, Double-Blind, Dose-Defining Trial in a Tb Endemic Setting

Number of pages: 22 Posted: 31 May 2024
University of Cape Town (UCT) - South African Tuberculosis Vaccine Initiative, University of Cape Town (UCT) - South African Tuberculosis Vaccine Initiative, University of Cape Town (UCT) - South African Tuberculosis Vaccine Initiative, University of Cape Town (UCT) - South African Tuberculosis Vaccine Initiative, University of Cape Town (UCT) - South African Tuberculosis Vaccine Initiative, University of Cape Town (UCT) - South African Tuberculosis Vaccine Initiative, University of Cape Town (UCT) - South African Tuberculosis Vaccine Initiative, University of Cape Town (UCT) - South African Tuberculosis Vaccine Initiative, University of Cape Town (UCT) - South African Tuberculosis Vaccine Initiative, University of Cape Town (UCT) - South African Tuberculosis Vaccine Initiative, University of Cape Town (UCT) - South African Tuberculosis Vaccine Initiative, University of Cape Town (UCT) - South African Tuberculosis Vaccine Initiative, University of Cape Town (UCT) - South African Tuberculosis Vaccine Initiative, University of Cape Town (UCT) - South African Tuberculosis Vaccine Initiative, Biofabri, Biofabri, Mukherjee Consultants, Biofabri, Biofabri, Biofabri, Biofabri, University of Zaragoza, University of Zaragoza, University of Zaragoza, University of Zaragoza, University of Cape Town (UCT) - South African Tuberculosis Vaccine Initiative and University of Cape Town (UCT) - South African Tuberculosis Vaccine Initiative
Downloads 116 (613,149)

Abstract:

Loading...

tuberculosis, newborns, vaccine, BCG, MTBVAC